Editas Medicine

+$0.12 (+0.60%) As of 7:04 PM UTC today

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EDIT and other ETFs, options, and stocks.

About EDIT

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9).

CEO

James C. Mullen

Employees

235

Headquarters

Cambridge, Massachusetts

Founded

2013

EDIT Key Statistics

Market cap

Price-Earnings ratio

—

Dividend yield

—

Average volume

1.86M

High today

$20.54

Low today

$19.63

Open price

$20.14

Volume

1.35M

52 Week high

$76.90

52 Week low

$19.63

EDIT News

Simply Wall StJan 14

What Kind Of Investors Own Most Of Editas Medicine, Inc.?

If you want to know who really controls Editas Medicine, Inc. (NASDAQ:EDIT), then you'll have to look at the makeup of its share registry. Insiders often own a

Analyst ratings

Buy

50%

Hold

37.5%

Sell

12.5%

EDIT Earnings

-$1.00

-$0.63

-$0.25

$0.12

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Estimated

— per share

Actual

Expected Feb 24, Pre-Market

Why Robinhood?

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). View more

What Kind Of Investors Own Most Of Editas Medicine, Inc.?

50%

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9).